# Impact of Specific Guidelines on Antimicrobial Use in a Large Mixed ICU



L. Senn, C. Plüss-Suard, P. Voirol, G. Zanetti, P. Eggimann Infection control, Pharmacy, CHUV, Adult Intensive Care Medicine, Lausanne, Switzerland

## BACKGROUND

Guidelines from the « surviving sepsis campaign » have emphasized on early use of empirical broad spectrum antibiotics. This may have increased their use, particularly in ICUs. Despite recommendations, audits showed that de-escalation is difficult to achieve. Antimicrobial use in our ICU is higher than those reported by other hospitals of the country. We investigate the impact of guidelines for antibiotic use.

## METHODS

Antimicrobial use in our 32-bed adult ICU was extracted from the pharmacy database (ATC J01, J04AB, P01AB). Defined daily doses (DDD) were adapted from WHO recommendations (1). ICU activity was extracted from the electronic patient file (Metavision<sup>®</sup>) and from the datawarehouse of the hospital.



Guidelines for antibiotic use were introduced in May 2008 and summarized in a pocket booklet distributed to all physicians. A one-hour session targeted at antimicrobial use was integrated into the ICU-introducing course in 2008 and completed by biannual specific sessions. These guidelines were further integrated into the ICU intranet with all other recommendations/protocol for patient care. Procalcitonin (PCT)-based de-escalation was introduced concomitantly.

### RESULTS

The global activity increased continuously over time (Table). A mean of 183 (+/- 22) dosages of procalcitonin were performed monthly in 2009. In contrast to this sustained increase in some risk factors, we observed a stabilization of the antimicrobial use since 2008, with a slight decrease in 2009.

	120			Guidel	Guidelines CHUV + SMIA	
Other	120					
Levofloxacin (iv)	100 -					
Amoxicillin-clavulanic acid (po)			30%	27%	26%	
Flucloxacillin (iv)	£ 80 −			3%		
Ceftriaxone (iv)		30%	2% 3% 6%	4% 5%	2% 3% 3%	
Clarithromycin (iv)	60 -	2%	4% 4%	5%	5%	
■ Imipenem-cilastatine (iv)		5%	9%	8%	8%	
■ Vancomycin (iv)	- - - -	8%	6%	9%	10%	
Piperacillin-tazobactam (iv)	ے ا	5% 8%	10%			
Amoxicillin-clavulanic acid (iv)	20 -	16%	15%	17%	16%	
Meropenem (iv)		2.49/	10%	14%	16%	
	0	14%	10%			
		2006	2007	2008	2009	
CU stays		2231	2312	2246	2229	
atient-days		10115	10790	10645	11206	
lean length of ICU stay (days)		4.3	4.4	4.4	4.7	
lechanical ventilation-days		3424	3855	4217	5112	
Catheter-days		8615	9332	10145	11168	

### CONCLUSION

Introduction of specific guidelines supported by continuous education and training may have contributed to stabilize the antimicrobial use in our mixed ICU.